Conference Correspondent

Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

Currently, comparative data are scarce in the literature to help guide treatment for previously untreated patients with Waldenström’s macroglobulinemia (WM), a rare subtype of non-Hodgkin lymphoma. In this study, researchers compared 3 commonly used regimens in WM: rituximab plus bendamustine (R-Benda); dexamethasone, rituximab, and cyclophosphamide (DRC); and bortezomib, dexamethasone, and rituximab (BDR).

This single-institution, retrospective study included patients with active WM, seen between 2000 and 2018, who received R-Benda, DRC, or BDR as primary therapy.

The study included 222 patients with active WM (R-Benda, n = 83; DRC, n = 92; BDR, n = 47). The median follow-up for the entire cohort was 4.0 years. Most baseline characteristics were similar across the 3 cohorts.

In terms of efficacy, objective response rates were 95%, 76%, and 81%, and major response rates were 93%, 46%, and 63% for R-Benda, DRC, and BDR, respectively. Median event-free survival was not reached, 4.3 years, and 2.1 years for R-Benda, DRC, and BDR, respectively. The difference in median 4-year overall survival between the 3 groups was not significant.

Hematologic and nonhematologic toxicities were similar across the 3 groups except for higher neuropathy leading to treatment discontinuation in patients who received BDR. Grade 3 neuropathy requiring treatment discontinuation was seen in 13% of patients treated with BDR.

This retrospective analysis showed that several efficacy outcomes with frontline R-Benda were superior in comparison with frontline DRC or BDR in patients with WM. In addition to the inherent limitations of retrospective studies, the researchers cautioned that shorter follow-up in the R-Benda group (median 2.2 years) versus the DRC (median 5.7 years) and BDR (median 4.7 years) groups may limit accurate assessment of long-term outcomes with R-Benda.

Abstract 7509; Abeykoon JP, et al.

Related Items
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME